Clinical trial
Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation
NCT00589316 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 5, 2007
- Completion date
- October 1, 2021
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, cd45-positive neoplastic cells present, chronic myelomonocytic leukemia, previously treated myelodysplastic syndrome, refractory anemia with excess blasts, refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory cytopenia with multilineage dysplasia and ring sideroblasts